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Streptozotocin (STZ) (2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose) is a naturally occurring
diabetogenic compound, produced by the soil bacterium streptomyces achromogenes, that exhibits broad spectrum of
antibacterial properties. Streptozotocin functions as a DNA synthesis inhibitor in both bacterial and mammalian cells. In
mammalian cells, the actual mechanism and metabolic targets of STZ toxicity that results in cell death is not known. This
review identifies four key areas that explain the mechanism of the cytotoxicity of STZ in mammalian cell lines, investigates
the practical aspects of using STZ in experimental animals and the potential risks of its exposure to human health.
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Streptozotocin (STZ) (2-deoxy-2-(3-methyl-3-nitrosourea)-
1-D-glucopyranose) is a naturally occurring compound,
produced by the soil bacterium streptomyces achromogenes,
that exhibits broad spectrum of antibacterial properties [1].
It is a mixture of α- and β-stereoisomers that appear as
pale yellow or off-white crystalline powder.
In terms of solubility, it is very soluble in water, ketones
and lower alcohols, but slightly soluble in polar organic
solvents [2]. Streptozotocin has a molecular formula of
C8H15N3O7, molecular weight of 265 g/mol and the struc-
ture is composed of nitrosourea moiety with a methyl
group attached at one end and a glucose molecule at the
other end [1].
STZ is a cytotoxic glucose analogue. After its discovery,
it was being used as a chemotherapeutic alkylating agent
in the treatment of metastasizing pancreatic islet cell tu-
mors and other malignancies [3].
In the year 1963, Rakieten and colleagues reported
that STZ is diabetogenic [4]. From that time of discovery* Correspondence: eleazon@yahoo.com
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stated.till date, STZ has been one of the chemical agents for
the induction of diabetes in experimental animals [5].
Streptozotocin functions as a DNA synthesis inhibitor
in both bacterial and mammalian cells [6]. In bacterial
cells, a specific interaction with cytosine moieties leads to
the degradation of the bacterial DNA [7]. Streptozotocin
is cytotoxic to pancreatic β-cells and its effects can be seen
within seventy two hours after administration depending
on the dose administered [8].
In mammalian cells, the mechanism of action of STZ
that results in cell death was not fully identified, though
it was thought to be a result of DNA and chromosomal
damage brought forth by mechanisms involving free rad-
ical generation during STZ metabolism [6]. However, after
several years of research, the mechanism of action of STZ
that results in cell death has been elucidated. The chem-
ical properties of STZ are presented as follows:
A. It is a cytotoxic methyl nitrosourea moiety
(N-methyl-N-nitrosourea) attached to the glucose
(2-deoxyglucose) molecule.
B. It is a glucosamine derivative
C. It is a toxic beta cell glucose analogue
D. It is a hydrophilic compound
E. It is an alkylating agentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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(GlcNAc) analogue that is accumulated preferentially in
pancreatic β-cells via GLUT 2 transporter uptake [9].
G. It is relatively stable at pH 7.4 and 37°C at least for
up to I hr [10].
H. It has a biological half life of 5–15 minutes [11,12]
I. When reconstituted into a solution, it can be stored
at room temperature or refrigerator but must be
used within 12 hrs if stored at room temperature
and protected from sunlight.
Elucidation of the diabetogenic action of STZ
STZ induces diabetes in rats, mice, monkeys, hamsters,
rabbits and guinea pigs. The toxic action of STZ involves
its uptake into cells. Although nitrosourea compounds are
usually lipophilic which makes their uptake by cells very
quick, STZ on the contrary is a hydrophilic compound
due to hexose substitution which limits its uptake by cells.
The selective pancreatic beta cell toxicity and diabetic
condition, resulting from STZ induction, is related to
the glucose moiety in its chemical structure which en-
ables STZ to enter the beta cell via the low affinity glu-
cose 2 transporter in the plasma membrane [13] because
the β-cells of the pancreas are more active than other
cells in taking up glucose and so are more sensitive than
other cells to STZ challenge. This statement is validated
by the observation that insulin producing cells that do
not express this glucose transporter are resistant to STZ
toxicity [13] and only become vulnerable to the toxicity
of this compound after expression of the GLUT 2 trans-
porter protein in the plasma membrane [13]. Moreover,
other cells that express this GLUT 2 transporter such as
the hepatocytes and the renal tubular cells are also suscep-
tible to STZ. This explains why experimental animals,
inducted with STZ, tend to have renal and liver damage
[5,14]. In addition, non beta cells such as: α-cells as well as
the extra-pancreatic parenchyma remain intact after STZ
challenge, indicating the beta cell selective properties of
STZ [3]. STZ also causes cardiac and adipose tissue dam-
age and increases oxidative stress, inflammation, endothe-
lial dysfunction [15] with the concentrations of the drug or
its metabolites in the liver, kidney, intestine and pancreas
being consistently higher than those in the plasma.
STZ does not affect the pancreatic beta cells of humans
when used in the treatment of islet-cell carcinomas and
malignant carcinoid tumors in humans [1]. This resistance
of the human beta cells to STZ is attributed to the very
low level of the constitutive GLUT 2 transporter expres-
sion in the human beta cell [16-20].
Biochemical basis of the cytotoxicity of STZ that results in
cell death (apoptosis/necrosis)
STZ is a structural analogue of glucose (Glu) and N-
acetyl glucosamine (GlcNAc) (Figure 1). STZ is taken upby pancreatic β-cells via the GLUT 2 transporter where
it causes β-cell death by DNA fragmentation due to the
nitrosourea moiety as earlier mentioned. Three major
pathways associated with cell death are: (i) DNA methy-
lation through the formation of carbonium ion (CH3
+)
resulting in the activation of the nuclear enzyme poly
ADP-ribose synthetase as part of the cell repair mechan-
ism and consequently, NAD+ depletion; (ii) Nitric oxide
production (iii) Free radical generation as hydrogen per-
oxide [9,21].
Methylation of DNA
The DNA methylating activity of the methylnitrosourea
moiety of STZ [22], especially at the O6 position of
guanine, leading to DNA damage with resultant necrosis
of the pancreatic beta cells, through the depletion of cel-
lular energy stores, is one explanation for the cell death
that results from STZ induction. The resultant activation
of polyADP-ribose polymerase (PARP), in an attempt to
repair the damaged DNA, depletes the cellular NAD+
and consequently, ATP stores as a result of overstimula-
tion of DNA repair mechanisms [23]. Although STZ also
methylates proteins, this DNA methylation is most re-
sponsible for beta cell death, though STZ methylation of
proteins could also contribute to its toxicity to the beta
pancreatic cells.
In addition, inhibitors of this poly ADP ribose poly-
merase such as nicotinamide, inhibit the methylation of
DNA by STZ. For example, administration of nicotinamide
prior to the induction of STZ in experimental rats, protects
the pancreatic cells from the toxic actions of STZ as well
as prevents the development of a diabetic state [24]. STZ
could also react at other sites of DNA such as the ring ni-
trogen and exocyclic oxygen atoms of DNA bases, pre-
dominantly producing 7-methylguanine, 3-methyladenine
which leads to DNA breaks, activates poly-ADP-ribose
polymerase and subsequently depletes NAD+.
Nitric oxide (NO) production
Another possible mechanism of the diabetogenic action of
streptozotocin that results in cell death has been attributed
to its ability to act as nitric oxide donor in pancreatic cells
[25] which inhibits aconitase activity, leading to DNA al-
kylation and damage [26]. Streptozotocin has been shown
to increase the activity of guanyl cyclase and the formation
of cGMP, which are characteristic actions of NO. β-cells
are particularly sensitive to damage by nitric oxide and free
radicals because of their low levels of free radical scaven-
ging enzymes [27].
Reactive Oxygen Species (ROS) Production in Oxidative Stress
Oxidative stress is defined as an imbalance between the
pro-oxidants and antioxidant defense system of the body




































Figure 1 Structures of (a) glucose (b) N-acetyl glucosamine (c) Streptozotocin and (d) methylnitrosourea.
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part, for pancreatic β-cell dysfunction caused by glucose
toxicity in hyperglycemia. Several reaction mechanisms are
thought to be involved in the genesis of oxidative stress in
both diabetic patients and diabetic animals and they in-
clude: glucose auto-oxidation, protein glycation, formation
of advanced glycation products and the polyol pathway
[28,29]. During these processes, ROS are produced and
cause tissue damage [30,31]. STZ treatment causes signifi-
cant increase in malonaldehyde but decreases antioxidant
enzymes such as: catalase, glutathione peroxidase and su-
peroxide dismutase activities when compared with control
animals in experiments. Decreases in antioxidant activities,
and simultaneous increases in malonaldehyde (MDA) ac-
tivities, indicate the susceptibility of pancreas to STZ’s in-
duction of oxidative stress [32,33].
One important involvement of ROS during STZ me-
tabolism is the production of uric acid as the final product
of ATP degradation by xanthine oxidase from hypoxan-
thine. This reaction generates ROS such as superoxide
and hydroxyl radicals emanating from H2O2 dismutation
during hypoxanthine metabolism, accelerating the process
of beta cell destruction. This is coupled with the fact that
the pancreatic beta cell is devoid of catalase and glutathi-
one peroxidase. The hydrogen peroxide subsequently gen-
erates free radicals such as O2- and OH-. These reactive
compounds can cause peroxidation of lipids, resulting
in the formation of hydroperoxy fatty acids and endo-
peroxides. This increases the formation of malonaldehyde
and thromboxane-B2 (TxB2). The accumulation of TxB2
along with thromboxane-A2 (TxA2) can cause plateletaggregation and promote thrombosis [34]. Increased ROS
production has also been reported to inhibit aconitase
which protects mitochondrial DNA (mtDNA) from deg-
radation [35].
Altered NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) based cell signaling
A fourth biochemical mechanism for the cytotoxicity of
STZ that results in cell death is through altered NF-κB
based cell signaling.
STZ selectively inhibits the activity of the glycoside
hydrolase O-GlcNAcase (enzyme O-GlcNAcase catalyzes
the cleavage of beta-O-linked GlcNAc (O-GlcNAc) from
modified proteins and is a member of the family 84 glyco-
side hydrolases) in the β-cell, which is responsible for re-
moving O-GlcNA from proteins. This causes irreversible
O-glycosylation of intracellular proteins resulting in β-cell
apoptosis [36,37]. STZ induces beta-cell dysfunction and
apoptosis at lower doses while causing beta-cell necrosis
at higher doses [38].
Doses (up to 15 mM) of STZ induce pancreatic beta-
cell death by inducing apoptosis followed by necrosis at
higher doses (up to 30 mM) [39]. Some other researchers
reported that STZ challenge (up to 20 mM) caused only
apoptotic cell death in other cellular systems [40]. In vitro
studies using insulin secreting insulinoma cells, keratino-
cytes and genetically engineered hepatocytes have also
shown that STZ (up to 20 mM) causes oxidative stress and
apoptosis [40].
However, the actual molecular mechanism and meta-
bolic targets of STZ toxicity in hepatocytes was not
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in human hepatoma was also not clearly understood.
Using the mitochondrial dehydrogenase based cellular
viability MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assay to investigate the dose- and
time-dependent effects of STZ on human hepatoma
(HepG2 cells) in culture, Haider and Annie [38] showed
that STZ induced significant cell death after 48 h of in-
duction with 20 mM of the drug. They also reported
that 10 mM STZ resulted in about 40% cell death. At
this dose, HepG2 cells exhibit increased ROS and NO
production and an increase in lipid peroxidation. The in-
crease in oxidative stress was associated with increased
apoptosis of HepG2 cells as evidenced by an increase in
caspase-3 activity and reduction in the expression of
anti-apoptotic protein, Bcl-2. They further reported that
the increased oxidative stress, apoptosis and mitochondrial
dysfunction in human hepatoma (HepG2) cells might be
associated with altered NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells, a protein complex that
controls the transcription of DNA found in all animal cell
types and is involved in cellular response to stimuli, free
radicals, oxidized LDL, bacterial or viral antigens) based
cell signaling as STZ increases the expression of iNOS (in-
ducible nitric oxide synthase) and translocation of NF-
κBp65 (RelA) transcription factor to the nucleus.
Practical aspects of using Streptozotocin in
experimental animals
Streptozotocin and induction of diabetes in animal species
STZ has proven to be a better diabetogenic agent than
alloxan with wider species effectiveness and greater re-
producibility. This could be attributed to the fact that
STZ is more stable in solution before and after injection
in animals than alloxan. In addition, alloxan causes a
decrease in hepatic glycogen within 24–72 hours, with
greater cytotoxicity due to its conversion to anionic radi-
cals [12] and pancreatic destruction, which insulin par-
tially reverses. Moreover, the STZ model mimics many
of the acute and chronic complications of human dia-
betes and given the established similarities of some of
the structural, functional and biochemical abnormalities
to human disease, it is an appropriate model to assess
the mechanism of diabetes.
When reconstituted into a solution, STZ can be stored
at room temperature or refrigerator but must be used
within 12 hrs if stored at room temperature and pro-
tected from sunlight. Due to streptozotocin’s alleged in-
stability in solution, the typical recommendation is to
administer it within 10 minutes after dissolution.
The American Diabetes Association [41] established an
etiologic classification of Diabetes mellitus and based on
their classification, four groups were proposed: 1) Type 1
(5–10%); 2) Type 2 (90–95%); 3) Other specific types and4) Gestational. Thus, STZ-induced diabetes belongs to the
category of other specific types or Drug (chemical) in-
duced diabetes. However, many researchers conclude that
STZ produces type I diabetes mellitus [42].
The type of diabetes induced by STZ is controversial
because STZ-hyperglycemia can be similar to either type
I or type II diabetes mellitus [42,43]. The dose of STZ
required for inducing diabetes depends on the animal
species, age of animal, route of administration, weight of
animal, nutritional status [44] and different responses to
xenobiotics. For injection in experimental animals and
for optimum results, it is best to be administered at fast-
ing state and freshly prepared, dissolved in citrate buffer
(pH 4.4-4.5).
Diabetogenic doses vary with species and the optimal
doses that have been reported to produce maximum dia-
betic conditions in various species are: rats (50 to 75 mg/kg
ip(intraperitoneal) [14,25,34,45,46], mice (175 to 200 mg/kg
ip or iv (intravenous) [11]; dogs (15 mg/kg for 3 days) [11].
At lower doses, STZ-induced diabetes is not stable, since
spontaneous recovery occurs.
In the study carried out by Ventura et al. [9], they re-
ported that a single high dose of 130 or 150 mg/kg bwt
or multiple doses of 40 mg/kg bwt produced hypergly-
cemia similar to type I diabetes and three administra-
tions of multiple low dose generated mild hyperglycemia
(250–450 mg/dl), that is similar to type II diabetes in ex-
perimental mice.
When administered intravenously, the binding of STZ
to its target site is completed within a short time and
plasma levels of STZ rapidly decrease within 15 minutes
and concentrate in the liver and kidneys [47,48]. As much
as twenty percent of the drug (or metabolites containing
an N-nitrosourea group) is metabolized and/or excreted
by the kidneys [48]. Thus the biochemical changes ob-
served after 15 minutes of STZ induction are secondary
changes and not due to a direct effect of STZ [5]. Compli-
cations from any toxic effect of streptozotocin were mini-
mized by carrying out the experiments four to five weeks
after the initial streptozotocin injection [45].
Some authors [8] described a triphasic response in blood
glucose after streptozotocin administration. According to
their study, in the first two hours of STZ challenge, blood
glucose rises. This transient hyperglycemia is due to sud-
den breakdown of liver glycogen. The second phase, start-
ing at about 6 hours after STZ dosing, is a hypoglycemic
one, which may be severe enough to lead to death. The
third phase, that of permanent hyperglycemia, begins at
about 10 to 12 hours after STZ administration. Structural
alterations in pancreatic beta cells (total degranulation)
occur within 48 h after the administration of streptozocin
and last for up to four months [12].
However, in the study carried out by Eleazu et al. [14]
and Adeghate and Ponery [49], they reported that the
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days post STZ administration, reaching its peak at 2 to
4 weeks in rats, leaving less active cells that result in a
diabetic state.
In clinical research studies investigating the ameliorat-
ing actions of some medicinal plants in diabetic animals
induced with STZ, its best to commence administration
of the test plants about two weeks post STZ induction
or about 11 days after initial hyperglycemic levels since
some animals have the ability to return to normogly-
cemic levels even after initial hyperglycemic levels. Thus
if such measures are not taken, one will not know if the
transformation to normoglycemic level is as a result of
the test plants administered or the animal’s ability to
withstand the initial STZ challenge.
Streptozotocin administration at fasting state
Researchers using diabetic animals for research employ
16–24 hours fasting, but this fasting brings about im-
portant changes. These changes tend to affect internal
cellular biochemistry and one should therefore expect
differences in the effects of preparations on isolated cells,
tissue or organs removed from animals that have, or have
not been fasted. Fasting has pronounced effects on clinical
chemistry analysts and hematology in diabetic animal
models. Hypoglycaemia for instance, is more pronounced
in fasted animals, therefore STZ should be administered
to fed animals to avoid mortalities [50].
Thus researchers using diabetic animal models for their
research should consider the effect of fasting for interpret-
ation of their results.
Although, one major reason for subjecting laboratory
animals to fasting before blood collection is to reduce
variability of some clinical chemistry parameters between
feeding and fasting conditions, intestinal physiologic func-
tions and drug-metabolizing enzymes may have some dif-
ference under feeding and fasting conditions. Thus, the
fasting in animals should be decided on a case by case
basis, rather than made uniform for every study.
Administration of 5% glucose solution during the first
24 hours following STZ injection has been reported to
prevent early mortalities [51,52].
The role of high fat diet (HFD) and low STZ dose in the
induction of type 2 diabetes
Injection of STZ (45 and 55 mg kg-1 intraperitoneally)
after 2 weeks of dietary manipulation has been reported
to cause hyperglycemia both in rats fed both normal pel-
let diet (NPD) and high fat diet [53]. Such rats were re-
ported to be insulin-deficient as compared to the normal
rats and exhibited a drastic reduction in the body weight
and some of them died within 2 weeks of STZ administra-
tion. In addition, insulinotropic (glipizide) and insulin-
sensitizing (pioglitazone) agents failed to alter the PGLin these fat-fed/STZ (45 and 55 mg kg−1) diabetic rats.
Thus, these fat-fed rats with high dose of STZ (45 and
55 mg kg−1) resembled more like type I diabetes. The
materialization of the disease pattern was achieved by
combining the feeding of HFD which produced insulin
resistance and low dose of STZ treatment that caused
the initial beta cell dysfunction and subsequently the
frank hyperglycemia (pre-diabetic state) in non-genetic,
out-bred Sprague–Dawley rats. The rats fed with high-
fat diet developed obesity, hyperinsulinemia, and insulin
resistance, thus limiting the screening of agents on con-
trolling the blood glucose level [53]. Interestingly, the in-
traperitoneal dose of STZ (35 mg/kg) that produced frank
hyperglycemia in HFD-fed rats failed to produce the same
in NPD-fed rats. The HFD rat model with low dose of
STZ (35 mg kg−1) was therefore considered by the authors
to represent the pathophysiological state of type 2 diabetes
as it was accompanied by marginal increase in body weight
in contrast to the catabolic loss of body weight, character-
istic of diabetic condition produced by high dose of STZ.Streptozotocin and hypernociception
Neuropathy is the most common chronic complication
of diabetes mellitus. One of the most elusive symptoms
in diabetic neuropathy is pain, characterized by mechan-
ical and thermal hyperalgesia [54]. Hypernociception in-
duced by systemic STZ administration has been widely
used as an animal model of diabetic neuropathy.
The pathophysiology of painful diabetes neuropathy is
unclear, although it has been associated with impaired
peripheral nerve conduction and degeneration of myelin-
ated and unmyelinated fibers [55]. To provide information
on underlying mechanisms and to evaluate potential ther-
apies, experimental research on diabetic neuropathy is
usually carried out using genetic or chemically induced
diabetic animal models. A systemic administration of STZ
has been reported to induce hyperalgesia to thermal, mech-
anical and chemical stimuli [56]. STZ induced hyperalgesia
is frequently associated with hyperglycemia because in
some studies its development was prevented by insulin
treatment [57,58]. STZ induced hyperalgesia is frequently
associated with hyperglycemia because in some studies its
development was prevented by insulin treatment [58,59].
Although these studies suggest that STZ induces painful
diabetic neuropathy, it is important to point out that the
majority of studies evaluating STZ-induced hyperalgesia
only include animals rendered hyperglycemic [60]. In the
study carried out by Cunha and colleagues [59], they re-
ported that administration of high dose (40 mg/kg bwt)
and low dose (10 or 20 mg/kg bwt) of Streptozotocin
produced mechanical hypernociception in all the STZ
challenged rats whereas the low dose failed to produce
hyperglycemia, suggesting that some other factor other
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mechanical hypernociception.
STZ: human toxicity and care in handling
The interaction with DNA and STZ’s ability to produce
cytotoxic effects in animals makes exposure to STZ a sig-
nificant health and safety threat to laboratory staff, animal
handlers, and other personnel who may be subjected to
accidental exposure. Due to this health and safety threat,
the Institutional Biosafety Committee (IBC) has classified
STZ as a reportable hazardous chemical that must be re-
ported on Institutional Animal Care and Use Committee
(IACUC) protocols.
Streptozotocin is anticipated to be a human carcinogen.
When administered intravenously, STZ has been shown
to induce tumors in rat kidney, liver and pancreas as earl-
ier mentioned in addition to neoplastic transformation in
primary human kidney cells at doses of 1 mM [61-63].
There are also speculations that STZ can lead to acute
complications such as: irritation, nausea, headache, vomit-
ing and chronic complications such as: reproductive disor-
ders, general deterioration of health as well as blindness if
in contact with the eyes.
Although there is no scientific evidence to validate such
claims, the International Agency for Research on Cancer
(IARC) emphasizes that STZ should be regarded for prac-
tical purposes as if it were carcinogenic to humans [64]
and as such, special care must be taken in preparing STZ
for practical use and one of such precautionary measure is
to prepare it inside a certified chemical fume hood.
Conclusion
The cytotoxicity of streptozotocin that results in death can
be explained on the basis of DNA methylation through the
formation of carbonium ion, resulting in the activation of
the nuclear enzyme poly ADP-ribose synthetase and con-
sequently, NAD+ depletion; Nitric oxide production, Free
radical generation as hydrogen peroxide generation and
through altered NF-κB based cell signal transduction path-
way. Although there is paucity of information on the car-
cinogenic effect of STZ on humans, when being used, it
should be regarded for practical purposes as if it were car-
cinogenic to humans. Finally, researchers using diabetic
animal models for their research should consider the effect
of fasting for the interpretation of their results.
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